Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...
Medscape3d
Over One Third of Patients Develop Exocrine Pancreatic Insufficiency After Acute Pancreatitis
A significant proportion of patients developed exocrine pancreatic insufficiency 12 months after a diagnosis of acute ...
Los Angeles Times6d
How AI can help researchers make esophageal cancer less deadly
Approximately 600 times a day, the esophagus ferries whatever is in your mouth down to your stomach. It’s usually a one-way route, but sometimes acid escapes the stomach and travels back up.
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data ...
Medscape4d
Prophylaxis of Hepatic Encephalopathy in Acute Variceal Bleed
From December 2008 to January 2010, patients with liver cirrhosis and acute gastrointestinal bleeding with hematemesis and/or malena within 24 h of presentation were included. The exclusion ...